Mark Dybul, a former United States Global AIDS Coordinator, was appointed Executive Director today of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Dybul is a member of GBCHealth’s Corporate Advisory Board and is a longtime supporter of GBCHealth.
“GBCHealth is delighted that Mark Dybul, who is not only an AIDS expert but a profound visionary, will lead the Global Fund,” said Michael Schreiber, Managing Director of GBCHealth. “Mark has the skills, passion and commitment to lead The Fund in its essential mission to attract and disburse resources to prevent and treat HIV and AIDS, TB and malaria."
Dybul is widely recognized as a visionary leader on global health for his role in helping create and then lead the President’s Emergency Program for AIDS Relief, known as PEPFAR, which has been highly effective in helping limit and reverse the growth of HIV infection worldwide. He currently co-directs the Global Health Law Program at the O’Neill Institute for National and Global Health Law at Georgetown University.
Additional Announcements: New Approach to Grant-Making
The Global Fund’s Board also announced other major developments at its meeting:
The Global Fund has approved a new approach to grant-making, completely overhauling its funding model. The new model places greater emphasis on an inclusive country dialogue and on alignment with a country's National Strategic Plans. The dialogue will include stakeholders such as country governments, private sector, civil society and the Global Fund Secretariat.
With the aim of simplifying grant making and allowing for flexibility in application timings, the model will also expedite disbursements and prioritize countries with the greatest need. Countries meeting set criteria will be invited to participate in the transition phase immediately, with full implementation slated for 2014. Participation in the transition phase is by countries with underfunded demand, at risk of service interruptions, with potential to achieve rapid impact, etc. Those not participating in the transition phase are encouraged to engage in-country stakeholders to determine grant needs and to develop national strategies, as initial steps in applying for funding under the new model.
These changes will make the grant process more inclusive, allowing greater participation and input from private sector companies. The Private Sector Delegation joined other Board constituencies in supporting this decision to make Global Fund grants more effective and achieve greater value for money.
The Board also agreed to incorporate lessons learned from its Phase 1 of the Affordable Medicines Facility - malaria (AMFm) into core Global Fund processes. The AMFm was created to improve access to artemisinin-based combination therapies (ACTs), the most effective anti-malaria treatment. Finally, the Board terminated the employment of Inspector General John Parsons “after a careful review of his performance, which was found to be unsatisfactory.”